►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".
►►Very important notification on publication fee
Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Professional and precise peer review
● Efficient and high-quality service
● International visibility and open access
● Large audience of CACA members
Announcements
Publication of the 4th issue in 2021 |
|
In order to report the latest advances in cancer immunology and immunotherapy, we published this special issue with sincere appreciation to the Guest Editor Prof. Xiubao Ren (Tianjin Medical University Cancer Institute & Hospital). In particular, his research on the role of ferritin in immune‑related adverse events is recommended. Besides, Prof. Yusuke Nakamura (Japanese Foundation for Cancer Research) summarized personalized immunotherapy in cancer precision medicine; and Prof. Xiaojun Huang (Peking University People’s Hospital) highlighted the developments of cellular immunotherapy in hematology. The contents also involve immune evasion, tumor immune microenvironment, immune checkpoint inhibitor, CAR-T cells in treatment, and so on. We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine. |
|
| Posted: 2021-11-09 | |
Publication of the 3rd issue in 2021 |
|
In this issue, Prof. Ning Zhang et al. from Peking University First Hospital (China) commented on the role of midlobular zone 2 hepatocytes in regeneration under homeostatic and injured liver conditions. Conclusion from the review written by Prof. Lin Fang et al. indicated that circular RNAs can be as potential diagnostic and prognostic markers, as well as the therapeutic targets for breast cancer. In another review, Prof. Joseph P. Balthasar et al. summarized the antibody therapies in solid tumors, and the strategies on enhancing monoclonal antibody uptake and distribution. Among the original articles, Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma authored by Prof. Tongyu Lin et al. is specially recommended. They concluded that the modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population, with a lower toxicity than standard regimens. We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.
|
|
| Posted: 2021-08-09 | |
| More Announcements... |
Vol 19 (2022): Online first articles
Table of Contents
Original Article
| Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma | |
| Ming Bai, et al. | 1-12 |
OUR FRIENDS
